The Impact of Using Genotyped Reagent Red Blood Cells in Antibody Identification

Scharberg, Erwin A.; Rink, Gabi; Portegys, Jan; Rothenberger, Sina; Gillhuber, Nicole; Richter, Ekkehard; Bugert, Peter

doi:10.1159/000491884

Cited by 15 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The maintenance of cellular membrane structure and antigens are the most crucial aspects for the transfusion medicine 41,42 . Agglutination assay is globally used in transfusion medicine.…”

Section: Discussionmentioning

confidence: 99%

Rapidly freeze‐dried human red blood cells for pre‐transfusion alloantibody testing reagents

Alves

Garnier

2021

J Biomed Mater Res

View full text Add to dashboard Cite

Prior to transfusion of red blood cells (RBCs), recipients must be tested for the presence of alloantibodies to avoid immune complications. Liquid‐preserved reagent RBCs with known blood group antigen phenotypes are used for testing. However, these reagents have practical constraints, including limited shelf‐life and require constant refrigeration. To address these issues, we explore the effects of rapid freeze‐drying conditions with trehalose cryoprotectant (0.1–1 M concentrations) on human RBCs and storage of freeze‐dried RBCs (FDRBCs) at room temperature (RT) for up to 12 months. We report that rapid freeze‐drying of RBCs for 2.5 hr with 0.5 M trehalose achieves recoverable cells with near‐normal morphological shape, although size‐reduced. The FDRBCs are metabolically active and functional in antibody‐agglutination tests by the column agglutination test (CAT) for ABO and Rhesus‐D blood group antigens. Expression of the Duffy blood group protein (CD234) decreases by 50% after freeze‐drying RBCs. The initial recovery rate is ≤25%; however, 43% of these FDRBCs are still recoverable after RT storage for 12 months. In this proof‐of‐principle study, we show that rapid freeze‐drying can stabilize RBCs. Further refinements to improve the recovery rate and preservation of antigenic epitopes will make FDRBCs a practical alternative source of reagent RBCs for pre‐transfusion alloantibody identification.

show abstract

“…The maintenance of cellular membrane structure and antigens are the most crucial aspects for the transfusion medicine 41,42 . Agglutination assay is globally used in transfusion medicine.…”

Section: Discussionmentioning

confidence: 99%

Rapidly freeze‐dried human red blood cells for pre‐transfusion alloantibody testing reagents

Alves

Garnier

2021

J Biomed Mater Res

View full text Add to dashboard Cite

show abstract

“…The SNVs encoding known KN antigens and p.His1208Arg were genotyped by using polymerase chain reaction–sequence‐specific priming methods as described 10 . The following primers were used: for dbSNP No.…”

Section: Methodsmentioning

confidence: 99%

Two novel antithetical KN blood group antigens may contribute to more than a quarter of all KN antisera in Europe

Grueger

Zeretzke²,

Habicht³

et al. 2020

Transfusion

Self Cite

View full text Add to dashboard Cite

Background All antigens described in the KN blood group system are located in the long homologous repeat D (LHR‐D) of complement receptor 1 (CR1). While there have been reports that some sera react only with the long homologous repeat C (LHR‐C), the antigens in LHR‐C are unknown. Study Design and Methods Recombinant LHR‐C and LHR‐D were used to identify antibodies directed against LHR‐C of CR1, into which a point mutation was introduced to characterize the underlying blood group antigens. In addition, database studies to define haplotypes of CR1 were performed. Results Several antisera were identified that were specific against CR1 p.1208His and against CR1 p.1208Arg, located in LHR‐C. Fifteen KN haplotypes were found in the Ensembl genome browser. It was shown that due to a linkage disequilibrium anti‐CR1 p.1208His may be mistaken for anti‐KCAM. Conclusion A novel antithetical KN blood group antigen pair was found at position p.1208 of CR1, for which the names DACY and YCAD are proposed. Antibodies against these two novel antigens seem to contribute to more than a quarter of all KN sera in Europe.

show abstract

“…NGS typing of all blood group genes in these "products" will upgrade the interpretation of serological results and antigen matching. 84…”

Section: Applications Of Ngs In Transfusion Medicinementioning

confidence: 99%

<p>Potential of next-generation sequencing to match blood group antigens for transfusion</p>

Orzińska¹,

Guz²,

Brojer³

2019

IJCTM

View full text Add to dashboard Cite

A review of the advances in applying next-generation sequencing (NGS) to transfusion medicine for the purpose of genotyping alleles encoding clinically important red blood cell and platelet antigens. NGS data from published studies confirm the possibility of antigen prediction based on sequencing of the whole genome, exome or targeted regions. What remains a challenge, to provide highly accurate NGS genotyping, is the further improvement of bioinformatic solutions for automated interpretation based on publicly accessible and improved reference databases appropriate for NGS methods as well as validation of a method based on the examination of a large number of individuals. There is no doubt, however, as to the future of NGS as a supplementary test used to provide highly compatible blood as well as to reduce the risk of patient's alloimmunization. This is part of personalized medicine.

show abstract

The Impact of Using Genotyped Reagent Red Blood Cells in Antibody Identification

Cited by 15 publications

References 10 publications

Rapidly freeze‐dried human red blood cells for pre‐transfusion alloantibody testing reagents

Rapidly freeze‐dried human red blood cells for pre‐transfusion alloantibody testing reagents

Two novel antithetical KN blood group antigens may contribute to more than a quarter of all KN antisera in Europe

<p>Potential of next-generation sequencing to match blood group antigens for transfusion</p>

Contact Info

Product

Resources

About